Holen Sie sich die Stockscreener-App
1.13
0.00%
0.00
Handel nachbörslich:
1.13
Schlusskurs vom Vortag:
$1.13
Offen:
$1.14
24-Stunden-Volumen:
137.70K
Relative Volume:
0.26
Marktkapitalisierung:
$70.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-73.79M
KGV:
-0.6141
EPS:
-1.84
Netto-Cashflow:
$-77.44M
1W Leistung:
-2.59%
1M Leistung:
-3.42%
6M Leistung:
-27.56%
1J Leistung:
-69.38%
1-Tages-Spanne:
$1.13
$1.1725
1-Wochen-Bereich:
$1.12
$1.23
52-Wochen-Spanne:
$0.8332
$5.3899
Pyxis Oncology Inc Stock (PYXS) Company Profile
Firmenname
Pyxis Oncology Inc
Sektor
Branche
Telefon
(617) 221-9059
Adresse
321 HARRISON AVENUE, BOSTON
Vergleichen Sie PYXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.13 | 71.86M | 0 | -73.79M | -77.44M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-08-08 | Eingeleitet | Stifel | Buy |
| 2024-05-07 | Fortgesetzt | Jefferies | Buy |
| 2024-02-09 | Eingeleitet | BTIG Research | Buy |
| 2024-01-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-09-05 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-11-02 | Eingeleitet | Credit Suisse | Outperform |
| 2021-11-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Pyxis Oncology Inc Aktie (PYXS) Neueste Nachrichten
What analysts say about Pyxis Oncology Inc. stockSuperior risk-adjusted returns - jammulinksnews.com
What drives Pyxis Oncology Inc. stock priceFree Smart Trading Workshop - jammulinksnews.com
Is Pyxis Oncology Inc. a good long term investmentRapid portfolio appreciation - jammulinksnews.com
Pyxis Oncology Inc. Stock Analysis and ForecastExplosive market performance - jammulinksnews.com
Financial Review: Ainos (NASDAQ:AIMD) vs. Pyxis Oncology (NASDAQ:PYXS) - Defense World
what makes pyxis oncology inc. stock price move sharplyGrowth Optimized Stock Radar - Newser
Why Pyxis Oncology Inc. stock attracts strong analyst attentionFree Low-Risk Investment Plans - Newser
How Pyxis Oncology Inc. stock performs during market volatilityDaily Trade Opportunity - Newser
What makes Pyxis Oncology Inc. stock price move sharplyFree Access to Stock Community - Newser
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $9.00 Average Price Target from Analysts - Defense World
Pyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% – Time to Buy? - Defense World
Pyxis Oncology Appoints New Principal Financial Officer - The Globe and Mail
Pyxis Oncology announces retirement of CFO and COO Pamela Connealy By Investing.com - Investing.com South Africa
Pyxis Oncology, Inc. Announces CFO Changes, Effective July 1, 2025 - MarketScreener
Pyxis Oncology announces retirement of CFO and COO Pamela Connealy - Investing.com
Pyxis Oncology's Equity Incentives: A Strategic Gambit for Clinical Success? - AInvest
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 3000 Index - MarketScreener
Pyxis Oncology, Inc.(NasdaqGS: PYXS) dropped from Russell 2000 Index - MarketScreener
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Pyxis Oncology Inc (PYXS) Stock: Navigating a Year of Stock Volatility - investchronicle.com
Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14 - Yahoo Finance
Pyxis Oncology shareholders elect three directors at annual meeting - Investing.com
Pyxis Oncology Elects New Directors at Annual Meeting - TipRanks
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Takes $35,000 Position in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Jane Street Group LLC Grows Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Nuveen Asset Management LLC Cuts Stake in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Pyxis Oncology, Inc. (NASDAQ:PYXS) Shares Sold by Deutsche Bank AG - Defense World
ProShare Advisors LLC Makes New Investment in Pyxis Oncology, Inc. (NASDAQ:PYXS) - Defense World
Finanzdaten der Pyxis Oncology Inc-Aktie (PYXS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):